Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai's EpimAb Forms Bi-Specific mAb Partnership with Kymab

publication date: Oct 11, 2016
EpimAb Biotherapeutics, a Shanghai startup, announced a cross-licensing and development deal with Kymab of the UK to develop bispecific therapeutic antibodies against several immuno-oncology targets. The partnership will use EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, which can generate multiple bispecific antibodies, and combine it with antibodies from Kymab’s Kymouse platform. EpimAb will own rights to the bispecifics in China; Kymab will have rights for the rest of the world. Each company will receive milestones and royalties for the other's programs. Further financial details were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital